Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option? (Q37827490)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

review article

1 reference

title

Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Vincenzo Solfrizzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Davide Seripa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Alberto Pilotto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Giancarlo Logroscino

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

language of work or name

English

0 references

publication date

11 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

325-341

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21222550%20AND%20SRC:MED&resulttype=core&format=json

2010 Alzheimer's disease facts and figures

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Forecasting the global burden of Alzheimer’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

A specific amyloid-beta protein assembly in the brain impairs memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Therapeutic potential of gamma-secretase inhibitors and modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Activity of gamma-secretase on substrates other than APP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without affecting Notch cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Gamma-secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Intramembrane proteolysis: theme and variations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Endogenous beta-amyloid production in presenilin-deficient embryonic mouse fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Presenilins are not required for A beta 42 production in the early secretory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

A presenilin-independent aspartyl protease prefers the gamma-42 site cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

In vitro reconstitution of gamma-secretase activity using yeast microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

The Proteolytic Fragments of the Alzheimer's Disease-associated Presenilin-1 Form Heterodimers and Occur as a 100–150-kDa Molecular Mass Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Presenilin and nicastrin regulate each other and determine amyloid beta-peptide production via complex formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Glu(332) in the Nicastrin ectodomain is essential for gamma-secretase complex maturation but not for its activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Nicastrin functions as a gamma-secretase-substrate receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Membrane topology of gamma-secretase component PEN-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Aph-1 contributes to the stabilization and trafficking of the gamma-secretase complex through mechanisms involving intermolecular and intramolecular interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Recent progress in the medicinal chemistry of gamma-secretase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

gamma-Secretase as a therapeutic target in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Neprilysin activity and expression are controlled by nicastrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Direct regulation of intestinal fate by Notch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Emerging role of Notch signaling in epidermal differentiation and skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Notch: from neural development to neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Learning and memory deficits in Notch mutant mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Involvement of Notch signaling in hippocampal synaptic plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

p53 is regulated by and regulates members of the gamma-secretase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Regulation of transcription of the human presenilin-1 gene by ets transcription factors and the p53 protooncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

p53-dependent control of transactivation of the Pen2 promoter by presenilins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Abeta40 inhibits amyloid deposition in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Mitochondrial Ca2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Tau reduction prevents Abeta-induced defects in axonal transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Alzheimer disease pathology as a host response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Neuropathology of older persons without cognitive impairment from two community-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Frequent amyloid deposition without significant cognitive impairment among the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572

Human β-Secretase (BACE) and BACE Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.550572